BLUE bluebird bio
- 1.240
- +0.100+8.77%
- 1.230
- -0.010-0.81%
bluebird bio News
Bluebird Bio (BLUE) Gets a Buy From Bank of America Securities
Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Bluebird Bio (BLUE) and Nuvalent (NUVL)
Bluebird Bio (BLUE) Receives a Hold From RBC Capital
Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Bluebird Bio (BLUE) and Viatris (VTRS)
William Blair Sticks to Its Hold Rating for Bluebird Bio (BLUE)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Bluebird Bio (BLUE)
Bluebird Bio Analyst Ratings
Bluebird Bio (BLUE) Receives a Hold From RBC Capital
Buy Rating Upheld for Bluebird Bio Amidst Revenue Miss and Promising Gene Therapy Launch
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Healthequity (HQY) and Bluebird Bio (BLUE)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE)
Hold Rating on Bluebird Bio Amidst Gradual Patient Starts and Funding Steps
Wedbush Adjusts Bluebird Bio Price Target to $1.72 From $1.68, Maintains Neutral Rating
Optimistic Outlook for Bluebird Bio: Buy Rating Affirmed on Extended Financial Runway and Profitability Prospects
Bluebird Bio Analyst Ratings
Wedbush Maintains Neutral on Bluebird Bio, Lowers Price Target to $1.68
Wedbush Adjusts Bluebird Bio's Price Target to $1.68 From $3, Maintains Neutral Rating
Bluebird Bio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Alcon (ALC)
Analysis
Price Target
No Data
